40 Gray in 5 Fractions for Salvage Reirradiation of Spine Lesions Previously Treated With Stereotactic Body Radiotherapy
- PMID: 38456696
- DOI: 10.1227/neu.0000000000002889
40 Gray in 5 Fractions for Salvage Reirradiation of Spine Lesions Previously Treated With Stereotactic Body Radiotherapy
Abstract
Background and purpose: A retrospective single-center analysis of the safety and efficacy of reirradiation to 40 Gy in 5 fractions (reSBRT) in patients previously treated with stereotactic body radiotherapy to the spine was performed.
Methods: We identified 102 consecutive patients treated with reSBRT for 105 lesions between 3/2013 and 8/2021. Sixty-three patients (61.8%) were treated to the same vertebral level, and 39 (38.2%) to overlapping immediately adjacent levels. Local control was defined as the absence of progression within the treated target volume. The probability of local progression was estimated using a cumulative incidence curve. Death without local progression was considered a competing risk.
Results: Most patients had extensive metastatic disease (54.9%) and were treated to the thoracic spine (53.8%). The most common regimen in the first course of stereotactic body radiotherapy was 27 Gy in 3 fractions, and the median time to reSBRT was 16.4 months. At the time of simulation, 44% of lesions had advanced epidural disease. Accordingly, 80% had myelogram simulations. Both the vertebral body and posterior elements were treated in 86% of lesions. At a median follow-up time of 13.2 months, local failure occurred in 10 lesions (9.5%). The 6- and 12-month cumulative incidences of local failure were 4.8% and 6%, respectively. Seven patients developed radiation-related neuropathy, and 1 patient developed myelopathy. The vertebral compression fracture rate was 16.7%.
Conclusion: In patients with extensive disease involvement, reSBRT of spine metastases with 40 Gy in 5 fractions seems to be safe and effective. Prospective trials are needed to determine the optimal dose and fractionation in this clinical scenario.
Copyright © Congress of Neurological Surgeons 2024. All rights reserved.
References
-
- McClelland S, Kim E, Passias PG, Murphy JD, Attia A, Jaboin JJ. Spinal stereotactic body radiotherapy in the United States: a decade-long nationwide analysis of patient demographics, practice patterns, and trends over time. J Clin Neurosci. 2017;46:109-112.
-
- Pathak RS, Tibdewal A, Kinhikar R, et al. Practice patterns and perspectives on stereotactic body radiation therapy for the metastatic spine from lower- and middle-income countries. JCO Glob Oncol. 2022;8(8):e2200167.
-
- Moussazadeh N, Lis E, Katsoulakis E, et al. Five-year outcomes of high-dose single-fraction spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2015;93(2):361-367.
-
- Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for Spinal Metastases: clinical experience in 500 cases from a single institution: clinical experience in 500 cases from a single institution. Spine. 2007;32(2):193-199.
-
- Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol. 2012;13(4):395-402.
MeSH terms
LinkOut - more resources
Full Text Sources